October a good month for Australian biotechs
November 1st 2006 07:04
Biotech Daily Special Report November 1, 2006
BIOTECH DAILY’S TOP 40
Most of the Biotech Top 40 increased in market capitalization in October with 22 companies rising at much greater rates than the 12 that fell. Six were unchanged.
Metabolic climbed by 79 percent for the month from $122 million to $216 million. Metabolic was as high as $2.20 a share in a brief spike in late 2004, falling as low as 38 cents in recent months. The positive announcements-led recovery puts Metabolic at about its eight year average (see Biotech Daily October 17, 2006).
Bionomics climbed 57 percent to $33 million; followed by Proteome up 39 percent to $46 million; Starpharma up 38 percent to $98 million; Pharmaxis up 28 percent to $510 million; Sirtex and Portland up 27 percent for the month to $163 million and $56 million respectively; with Progen and Cygenics up 19 percent to $142 million and $25 million respectively.
Just outside the Top 40 Apollo Life was up 21 percent to $29 million, Benitec recovered 200 percent from $5 million to $15 million, with IM Medical up 29 percent to $17 million.
The worst fall among Top 40 stocks was Phylogica’s 17 percent fall to $24 million, less than half of its April market capitalization and Novogen’s 14 percent slide to $260 million less than half the value of one year ago. Clinical Cell and Living Cell fell 14 and 12 percent respectively.
All three big caps climbed with Cochlear hitting a record high above $3.0 billion.
Eleven Top 20 stocks were up and eight fell over the month, with 11 of the Second 20 up and four down.
The Top 40 remains unchanged with Gropep expected to depart the ASX later this month. Stem Cell Sciences has been mentioned as possibly listing on the ASX in the not too distant future, with Apollo Life, IM Medical, Xceed Biotechnology, Biopharmica, Antisense and Sunshine Heart all worthy of promotion.
Company $A mil Nov-01 Oct-01 Sep-01
Big Caps
Cochlear - 3,056 - 2,909 - 2,760
CSL - 10,236 - 9,852 - 9,249
Resmed - 4,067 - 3,819 - 3,798
Top 20 - - - -
Acrux - 101 - 107 - 90
Alchemia - 88 - 88 - 79
Biosignal - 18 - 19 - 19
Biota - 237 - 239 - 222
Chemgenex - 76 - 73 - 70
Cytopia - 53 - 51 - 53
Mesoblast - 87 - 72 - 81
Metabolic - 218 - 122 - 128
Neuren - 49 - 46 - 42
Novogen - 260 - 302 - 260
Peplin - 116 - 112 - 109
Peptech - 210 - 215 - 203
Pharmaxis - 510 - 398 - 389
Phospha - 191 - 202 - 213
Phylogica - 24 - 29 - 35
Prana - 49 - 58 - 47
Progen - 142 - 119 - 111
Sirtex - 163 - 128 - 128
Starpharma - 98 - 71 - 68
Ventracor - 208 - 205 - 204
Second 20 - - - -
Agenix - 31 - 30 - 34
Avexa - 46 - 46 - 45
Bionomics - 33 - 21 - 18
Cellestis - 315 - 256 - 305
Clinical Cell - 19 - 22 - 25
Clinuvel - 85 - 85 - 70
Cogstate - 8 - 9 - 12
Cygenics - 25 - 21 - 17
Evogenix - 61 - 58 - 61
Genetic Tech132 - 129 - 134
Gropep - 95 - 94 - 93
Living Cell - 22 - 25 - 28
Optiscan - 48 - 45 - 52
Polartech - 10 - 10 - 14
Portland - 56 - 44 - 42
Prima - 10 - 10 - 12
Proteome - 46 - 33 - 30
Psivida - 115 - 123 - 149
Tissue - 9 - 9 - 9
Uscom - 18 - 16 - 17
* Biotech Daily editor David Langsam owned shares in Alchemia, Biota, Clinical Cell, OBJ and Psivida at the time of publication, along with a portfolio of non-biotech shares. These holdings are liable to change at any time.
Other stories in today’s Biotech Daily
available by daily email subscription
click here
* ASX UP, BIOTECHS DOWN: AGENIX UP 10%, CYGENICS DOWN 12%
* ADVANCED OCULAR TO BUY NEW LENS TECHNOLOGY
* CLINUVEL RAISES $35.2m
* NORWOOD'S VANISHING IMMUNOLOGY
* LIFE THERAPEUTICS SELLS AUSTRALIAN ASSETS
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
OCTOBER A GOOD MONTH FOR BIOTECHS
BIOTECH DAILY’S TOP 40
Most of the Biotech Top 40 increased in market capitalization in October with 22 companies rising at much greater rates than the 12 that fell. Six were unchanged.
Metabolic climbed by 79 percent for the month from $122 million to $216 million. Metabolic was as high as $2.20 a share in a brief spike in late 2004, falling as low as 38 cents in recent months. The positive announcements-led recovery puts Metabolic at about its eight year average (see Biotech Daily October 17, 2006).
Bionomics climbed 57 percent to $33 million; followed by Proteome up 39 percent to $46 million; Starpharma up 38 percent to $98 million; Pharmaxis up 28 percent to $510 million; Sirtex and Portland up 27 percent for the month to $163 million and $56 million respectively; with Progen and Cygenics up 19 percent to $142 million and $25 million respectively.
Just outside the Top 40 Apollo Life was up 21 percent to $29 million, Benitec recovered 200 percent from $5 million to $15 million, with IM Medical up 29 percent to $17 million.
The worst fall among Top 40 stocks was Phylogica’s 17 percent fall to $24 million, less than half of its April market capitalization and Novogen’s 14 percent slide to $260 million less than half the value of one year ago. Clinical Cell and Living Cell fell 14 and 12 percent respectively.
All three big caps climbed with Cochlear hitting a record high above $3.0 billion.
Eleven Top 20 stocks were up and eight fell over the month, with 11 of the Second 20 up and four down.
The Top 40 remains unchanged with Gropep expected to depart the ASX later this month. Stem Cell Sciences has been mentioned as possibly listing on the ASX in the not too distant future, with Apollo Life, IM Medical, Xceed Biotechnology, Biopharmica, Antisense and Sunshine Heart all worthy of promotion.
Company $A mil Nov-01 Oct-01 Sep-01
Big Caps
Cochlear - 3,056 - 2,909 - 2,760
CSL - 10,236 - 9,852 - 9,249
Resmed - 4,067 - 3,819 - 3,798
Top 20 - - - -
Acrux - 101 - 107 - 90
Alchemia - 88 - 88 - 79
Biosignal - 18 - 19 - 19
Biota - 237 - 239 - 222
Chemgenex - 76 - 73 - 70
Cytopia - 53 - 51 - 53
Mesoblast - 87 - 72 - 81
Metabolic - 218 - 122 - 128
Neuren - 49 - 46 - 42
Novogen - 260 - 302 - 260
Peplin - 116 - 112 - 109
Peptech - 210 - 215 - 203
Pharmaxis - 510 - 398 - 389
Phospha - 191 - 202 - 213
Phylogica - 24 - 29 - 35
Prana - 49 - 58 - 47
Progen - 142 - 119 - 111
Sirtex - 163 - 128 - 128
Starpharma - 98 - 71 - 68
Ventracor - 208 - 205 - 204
Second 20 - - - -
Agenix - 31 - 30 - 34
Avexa - 46 - 46 - 45
Bionomics - 33 - 21 - 18
Cellestis - 315 - 256 - 305
Clinical Cell - 19 - 22 - 25
Clinuvel - 85 - 85 - 70
Cogstate - 8 - 9 - 12
Cygenics - 25 - 21 - 17
Evogenix - 61 - 58 - 61
Genetic Tech132 - 129 - 134
Gropep - 95 - 94 - 93
Living Cell - 22 - 25 - 28
Optiscan - 48 - 45 - 52
Polartech - 10 - 10 - 14
Portland - 56 - 44 - 42
Prima - 10 - 10 - 12
Proteome - 46 - 33 - 30
Psivida - 115 - 123 - 149
Tissue - 9 - 9 - 9
Uscom - 18 - 16 - 17
* Biotech Daily editor David Langsam owned shares in Alchemia, Biota, Clinical Cell, OBJ and Psivida at the time of publication, along with a portfolio of non-biotech shares. These holdings are liable to change at any time.
Other stories in today’s Biotech Daily
available by daily email subscription
click here
* ASX UP, BIOTECHS DOWN: AGENIX UP 10%, CYGENICS DOWN 12%
* ADVANCED OCULAR TO BUY NEW LENS TECHNOLOGY
* CLINUVEL RAISES $35.2m
* NORWOOD'S VANISHING IMMUNOLOGY
* LIFE THERAPEUTICS SELLS AUSTRALIAN ASSETS
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 26 |
| Vote |
Add To: 
subscribe to this blog